(Q45344293)

13 December 2017

title

Mechanism of cytochrome P450-3A inhibition by ketoconazole (English)

1 reference

13 December 2017

5

Jerold S Harmatz

1 reference

13 December 2017

1

David J Greenblatt

1 reference

13 December 2017

8

Lisa L von Moltke

1 reference

13 December 2017

7

Michael H Court

1 reference

13 December 2017

Karthik Venkatakrishnan

series ordinal

3

object named as

Karthik Venkatakrishnan

1 reference

13 December 2017

Yanli Zhao

2

1 reference

13 December 2017

Su X Duan

series ordinal

4

1 reference

13 December 2017

Sarah J Parent

series ordinal

6

1 reference

13 December 2017

publication date

1 February 2011

1 reference

Journal of Pharmacy and Pharmacology

13 December 2017

published in

1 reference

13 December 2017

volume

63

1 reference

13 December 2017

issue

2

1 reference

13 December 2017

page(s)

214-221

1 reference

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Modelling atypical CYP3A4 kinetics: principles and pragmatism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Cooperativity in oxidations catalyzed by cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Heterotropic cooperativity in oxidation mediated by cytochrome p450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2010.01202.X

10.1111/J.2042-7158.2010.01202.X

21 January 2018

Identifiers

DOI

1 reference

13 December 2017

1 reference